Mark B Abelson

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi request reprint Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen cha
    Mark B Abelson
    Ora, Inc, Andover, Massachusetts 01810, USA
    Clin Ther 31:1908-21. 2009
  2. doi request reprint Dry eye in 2008
    Mark B Abelson
    Ora, Andover, MA 01810, USA
    Curr Opin Ophthalmol 20:282-6. 2009
  3. doi request reprint Antihistamines in ocular allergy: are they all created equal?
    Mark B Abelson
    Schepens Eye Institute, Boston, MA 02114, USA
    Curr Allergy Asthma Rep 11:205-11. 2011
  4. doi request reprint Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis
    Thomas T Macejko
    Eye Care Associates of Greater Cincinnati, Inc, Fairfield, Ohio, USA
    Am J Ophthalmol 150:122-127.e5. 2010
  5. doi request reprint Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge
    Gail L Torkildsen
    Andover Eye Associates, Andover, Massachusetts, USA
    Ann Allergy Asthma Immunol 105:57-64. 2010
  6. ncbi request reprint Efficacy and safety of ketotifen fumarate 0.025% in the conjunctival antigen challenge model of ocular allergic conjunctivitis
    Jack V Greiner
    Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts, USA
    Am J Ophthalmol 136:1097-105. 2003
  7. ncbi request reprint Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis
    Mark B Abelson
    Schepens Eye Research Institute, Boston, MA 01845, USA
    Curr Med Res Opin 21:683-91. 2005
  8. ncbi request reprint Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis
    Mark B Abelson
    Schepens Eye Research Institute and Harvard Medical School, Boston, Massachusetts, USA
    Allergy Asthma Proc 28:427-33. 2007
  9. ncbi request reprint Efficacy of ketotifen fumarate 0.025% ophthalmic solution compared with placebo in the conjunctival allergen challenge model
    Mark B Abelson
    Schepens Eye Research Institute and Department of Ophthalmology, Harvard Medical School, Boston, MA, USA
    Arch Ophthalmol 121:626-30. 2003
  10. ncbi request reprint Bioequivalence of two formulations of ketotifen fumarate ophthalmic solution: a single-center, randomized, double-masked conjunctival allergen challenge investigation in allergic conjunctivitis
    Gail L Torkildsen
    Andover Eye Associates, Andover, Massachusetts, 01845, USA
    Clin Ther 30:1272-82. 2008

Collaborators

Detail Information

Publications27

  1. doi request reprint Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen cha
    Mark B Abelson
    Ora, Inc, Andover, Massachusetts 01810, USA
    Clin Ther 31:1908-21. 2009
    ..Based on a history of clinical effectiveness and tolerability of oral bepotastine besilate in the treatment of allergic symptoms, bepotastine besilate is being tested as a potential ophthalmic medication for allergic conjunctivitis...
  2. doi request reprint Dry eye in 2008
    Mark B Abelson
    Ora, Andover, MA 01810, USA
    Curr Opin Ophthalmol 20:282-6. 2009
    ..Although researchers continue to investigate the multifarious etiologic, anatomical, physiological, and pathological factors of dry eye, successful treatment remains a challenge...
  3. doi request reprint Antihistamines in ocular allergy: are they all created equal?
    Mark B Abelson
    Schepens Eye Institute, Boston, MA 02114, USA
    Curr Allergy Asthma Rep 11:205-11. 2011
    ..Future development is likely to focus on long-acting agents such as these and on drugs that can target additional histamine receptor subtypes...
  4. doi request reprint Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis
    Thomas T Macejko
    Eye Care Associates of Greater Cincinnati, Inc, Fairfield, Ohio, USA
    Am J Ophthalmol 150:122-127.e5. 2010
    ..0% and 1.5% compared with placebo at reducing ocular itching and conjunctival hyperemia in the conjunctival allergen challenge (CAC) model of allergic conjunctivitis...
  5. doi request reprint Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge
    Gail L Torkildsen
    Andover Eye Associates, Andover, Massachusetts, USA
    Ann Allergy Asthma Immunol 105:57-64. 2010
    ..Bepotastine besilate is a selective histamine1-receptor antagonist and mast cell stabilizer with inhibitory effects on eosinophilic activity...
  6. ncbi request reprint Efficacy and safety of ketotifen fumarate 0.025% in the conjunctival antigen challenge model of ocular allergic conjunctivitis
    Jack V Greiner
    Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts, USA
    Am J Ophthalmol 136:1097-105. 2003
    ..To determine the duration of action of ketotifen 0.025% eye drops vs placebo taken as single or multiple doses in an allergen challenge model...
  7. ncbi request reprint Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis
    Mark B Abelson
    Schepens Eye Research Institute, Boston, MA 01845, USA
    Curr Med Res Opin 21:683-91. 2005
    ....
  8. ncbi request reprint Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis
    Mark B Abelson
    Schepens Eye Research Institute and Harvard Medical School, Boston, Massachusetts, USA
    Allergy Asthma Proc 28:427-33. 2007
    ..2% reduced the signs and symptoms of allergic conjunctivitis with a rapid and prolonged duration of action. Safety analyses indicated that olopatadine 0.2% was safe and well tolerated in subjects with a history of allergic conjunctivitis...
  9. ncbi request reprint Efficacy of ketotifen fumarate 0.025% ophthalmic solution compared with placebo in the conjunctival allergen challenge model
    Mark B Abelson
    Schepens Eye Research Institute and Department of Ophthalmology, Harvard Medical School, Boston, MA, USA
    Arch Ophthalmol 121:626-30. 2003
    ..Ketotifen fumarate blocks histamine1 (H1) receptors, stabilizes mast cells, and acts as an eosinophil inhibitor (decreases chemotaxis and activation of eosinophils)...
  10. ncbi request reprint Bioequivalence of two formulations of ketotifen fumarate ophthalmic solution: a single-center, randomized, double-masked conjunctival allergen challenge investigation in allergic conjunctivitis
    Gail L Torkildsen
    Andover Eye Associates, Andover, Massachusetts, 01845, USA
    Clin Ther 30:1272-82. 2008
    ..025% (test formulation) contains the same active ingredient in the same concentration as the reference formulation, is intended for twice-daily dosing, and may provide a treatment option in patients with AC...
  11. ncbi request reprint Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge
    Mark B Abelson
    Harvard Medical School, Schepens Eye Research Institute, Department of Ophthalmology, Boston, Massachusetts, USA
    Curr Eye Res 32:1017-22. 2007
    ..1% and one drop of olopatadine 0.2%. Both showed significant activity at the 24-hour time point and were statistically superior to placebo. No adverse events occurred while on drug therapy...
  12. ncbi request reprint Efficacy and safety of single- and multiple-dose ketotifen fumarate 0.025% ophthalmic solution in a pediatric population
    Mark B Abelson
    Schepens Eye Research Institute, Harvard Medical School, Boston, MA 01845, USA
    Pediatr Allergy Immunol 15:551-7. 2004
    ..No subject discontinued prematurely due to an adverse event. These results indicate that ketotifen fumarate 0.025% ophthalmic solution is an effective and safe treatment option for children with allergic conjunctivitis...
  13. ncbi request reprint One-visit, randomized, placebo-controlled, conjunctival allergen challenge study of scanning and imaging technology for objective quantification of eyelid swelling in the allergic reaction with contralateral use of olopatadine and artificial tears
    Mark B Abelson
    Harvard Medical School, Boston, Massachusetts, USA
    Clin Ther 25:2070-84. 2003
    ..The eyelids are more susceptible than other tissues to swelling, acute inflammation, and resultant long-term damage. However, no precise, objective means of measuring eyelid swelling in the clinical setting has been developed...
  14. ncbi request reprint Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental study
    Mark B Abelson
    Schepens Eye Research Institute, Boston, USA
    Clin Ther 26:1237-48. 2004
    ..Previous studies have suggested that olopatadine hydrochloride ophthalmic solution 0.2% administered once daily is effective for up to 24 hours after instillation and is well tolerated in adults and children aged > or =3 years...
  15. ncbi request reprint Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing
    Mark B Abelson
    Schepens Eye Research Institute, Boston, Massachusetts, USA
    Expert Opin Drug Metab Toxicol 4:453-61. 2008
    ..Olopatadine 0.2% is the first topical ophthalmic antihistamine/mast cell stabilizer indicated for once-daily dosing...
  16. ncbi request reprint Multicenter, open-label evaluation of hyperemia associated with use of bimatoprost in adults with open-angle glaucoma or ocular hypertension
    Mark B Abelson
    Department of Ophthalmology, Harvard Medical School, Schepens Eye Research Institute, Boston, Massachusetts, USA
    Adv Ther 20:1-13. 2003
    ..4% were somewhat or moderately troubled. Investigators indicated that they would continue bimatoprost therapy in 92.3% of the patients. Hyperemia did not represent a significant safety concern...
  17. doi request reprint Diurnal variation of visual function and the signs and symptoms of dry eye
    Pamela M Walker
    Ora, Inc, Andover, MA, USA
    Cornea 29:607-12. 2010
    ..To clinically substantiate these reports of diurnal variations, the present study tested subjects with dry eye on a series of visual function and ocular physiology measures...
  18. ncbi request reprint Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies
    Mark B Abelson
    Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts, USA
    J Ocul Pharmacol Ther 18:475-88. 2002
    ..1% was well tolerated and had a safety profile similar to that of placebo. In conclusion, pemirolast potassium 0.1% is effective and safe in preventing ocular itching in patients with allergic conjunctivitis during allergy season...
  19. ncbi request reprint Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis
    Scott M Whitcup
    Allergan, Inc, Irvine, California 92623 9534, USA
    Clin Ther 26:29-34. 2004
    ..Epinastine hydrochloride is an antihistamine with mast cell-stabilizing and anti-inflammatory activity...
  20. ncbi request reprint A review of olopatadine for the treatment of ocular allergy
    Mark B Abelson
    Harvard Medical School and Schepens Eye Research Institute, Boston, Massachusetts, USA
    Expert Opin Pharmacother 5:1979-94. 2004
    ..In the future, a new formulation containing 0.2% olopatadine exhibits a duration of action up to 24 h, supporting once-daily dosing...
  21. ncbi request reprint Ocular tolerability and safety of ketotifen fumarate ophthalmic solution
    Mark B Abelson
    Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA
    Adv Ther 19:161-9. 2002
    ..Ketotifen has a favorable safety and tolerability profile, which may have a positive impact on compliance, an important aspect of effective symptomatic control of allergic conjunctivitis...
  22. ncbi request reprint A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis
    Mark B Abelson
    Department of Ophthalmology, Harvard Medical School, Boston, USA
    Clin Ther 25:931-47. 2003
    ..Similarly, the primary symptoms of allergic rhinoconjunctivitis are nasal itching, irritation, sneezing, watery rhinorrhea, and congestion combined with ocular itching, tearing, and swelling...
  23. doi request reprint Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial
    Mark B Abelson
    Ophthalmic Research Associates, North Andover, Massachusetts, USA
    Am J Ophthalmol 145:959-65. 2008
    ..To analyze the effect of azithromycin 1% ophthalmic solution in DuraSite (InSite Vision, Inc, Alameda, California, USA) on bacterial conjunctivitis...
  24. pmc Automated grading system for evaluation of ocular redness associated with dry eye
    John D Rodriguez
    Ora, Inc, Andover, MA, USA
    Clin Ophthalmol 7:197-1204. 2013
    ....
  25. ncbi request reprint A randomized, double-blind, placebo-controlled comparison of emedastine 0.05% ophthalmic solution with loratadine 10 mg and their combination in the human conjunctival allergen challenge model
    Mark B Abelson
    Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts 02114, USA
    Clin Ther 24:445-56. 2002
    ..When selecting treatment for allergic conjunctivitis, a primary concern is whether to choose local or systemic therapy...
  26. pmc Investigation of extended blinks and interblink intervals in subjects with and without dry eye
    John D Rodriguez
    Ora, Inc, Andover, MA
    Clin Ophthalmol 7:337-42. 2013
    ..The purpose of this study was to investigate the occurrence and duration of extended blinks ≥ 70 msec and their associated interblink intervals in normal subjects and in subjects with mild to moderate dry eye...
  27. pmc The interblink interval in normal and dry eye subjects
    Patrick R Johnston
    Ora, Inc, Andover, MA, USA
    Clin Ophthalmol 7:253-9. 2013
    ..We hypothesized that this more comprehensive approach would better discriminate between normal and dry eye subjects...